TY - JOUR
T1 - Gender differences in antacid-induced phosphate deprivation in rats
AU - Schwarz, Kathleen B.
AU - Zimmerman, Debra C.
AU - Alpers, David H.
AU - Avioli, Louis V.
N1 - Funding Information:
Received July 20, 1984. Accepted January 22, 1985. Address requests for reprints to: Kathleen B. Schwarz, M.D., Cardinal Glennon Memorial Hospital for Children, 1465 South Grand, St. Louis, Missouri 63104. This study was supported in part by National Institutes Health Grant AM11674. The authors thank John Bracamontes, Zoe Goeckler, and Matthew Zahn for technical assistance and Sheryl Wunderlich for expert secretarial assistance. 0 1985 by the American Gastroenterological 0016.5085/85/$3.30
PY - 1985/8
Y1 - 1985/8
N2 - To determine whether an animal model could be used to study the susceptibility of women to antacid-induced phosphate deficiency, 6-wk-old male and female rats were given basic aluminum carbonate gel (Basaljel) (1 ml/100 g body wt) or distilled water by gastric intubation daily for 3 wk. Rats were fed either ad libitum (group 1) or by pair-feeding (group 2) with pelleted rat food containing 0.74% phosphorus. In group 1, baseline, 1-wk, and 3-wk values for serum phosphorus in Basaljel-treated females were 7.7 ± 0.2, 6.3 ± 0.2, and 6.2 ± 0.2 mg/dl, respectively. Corresponding values for control females were 7.8 ± 0.3, 7.0 ± 0.2, and 7.3 ± 0.2 mg/dl. Values for treated females were significantly lower (p < 0.02) than values for control females by 1 wk of treatment. Basaljel-treated males did not differ from controls. The pattern for group 2 was similar. Intestinal absorption and intramuscular stores of phosphate were assessed in group 1. After 3 wk of treatment, [32P]phosphate assimilation from the duodenum into the body was lower in Basaljel-treated females than in controls (33.8% ± 1.9% vs. 49.8% ± 6.2% of the luminally administered dose, p < 0.05). This was due to increased retention of [32P]phosphate in the intestine of treated females (19.9% ± 2.0% vs. 11.9% ± 2.4% for control females, p < 0.02). Results in jejunum were similar. Total intramuscular phosphate in females was significantly lower (p < 0.005) than in males both before and after antacid treatment. Thus hypophosphatemia in the female rat during antacid administration is probably secondary to the additive effects of decreased assimilation and decreased soft tissue stores of phosphate.
AB - To determine whether an animal model could be used to study the susceptibility of women to antacid-induced phosphate deficiency, 6-wk-old male and female rats were given basic aluminum carbonate gel (Basaljel) (1 ml/100 g body wt) or distilled water by gastric intubation daily for 3 wk. Rats were fed either ad libitum (group 1) or by pair-feeding (group 2) with pelleted rat food containing 0.74% phosphorus. In group 1, baseline, 1-wk, and 3-wk values for serum phosphorus in Basaljel-treated females were 7.7 ± 0.2, 6.3 ± 0.2, and 6.2 ± 0.2 mg/dl, respectively. Corresponding values for control females were 7.8 ± 0.3, 7.0 ± 0.2, and 7.3 ± 0.2 mg/dl. Values for treated females were significantly lower (p < 0.02) than values for control females by 1 wk of treatment. Basaljel-treated males did not differ from controls. The pattern for group 2 was similar. Intestinal absorption and intramuscular stores of phosphate were assessed in group 1. After 3 wk of treatment, [32P]phosphate assimilation from the duodenum into the body was lower in Basaljel-treated females than in controls (33.8% ± 1.9% vs. 49.8% ± 6.2% of the luminally administered dose, p < 0.05). This was due to increased retention of [32P]phosphate in the intestine of treated females (19.9% ± 2.0% vs. 11.9% ± 2.4% for control females, p < 0.02). Results in jejunum were similar. Total intramuscular phosphate in females was significantly lower (p < 0.005) than in males both before and after antacid treatment. Thus hypophosphatemia in the female rat during antacid administration is probably secondary to the additive effects of decreased assimilation and decreased soft tissue stores of phosphate.
UR - http://www.scopus.com/inward/record.url?scp=0021860988&partnerID=8YFLogxK
U2 - 10.1016/0016-5085(85)90331-2
DO - 10.1016/0016-5085(85)90331-2
M3 - Article
C2 - 2989074
AN - SCOPUS:0021860988
SN - 0016-5085
VL - 89
SP - 313
EP - 320
JO - Gastroenterology
JF - Gastroenterology
IS - 2
ER -